28th Jan 2021 14:40
Beximco Pharmaceuticals Ltd - Bangladesh-based medicine manufacturer - Reports profit after tax of GBP19.4 million for six months ended December 30, up 30% from GBP15.5 million in the 2019 equivalent period. Net sales for the period increased 15% to GBP125.8 million from GBP112.6 million the prior year, with domestic sales up 17% to GBP113.6 million from GBP100.0 million and export sales down 3.2% to GBP12.2 million from GBP12.6 million.
"We have delivered strong results in the first half of the year that demonstrate the resilience of the business and reinforce our commitment to ensure an uninterrupted supply of medicines despite macroeconomic headwinds caused by the ongoing Covid-19 pandemic. Looking ahead, we maintain a positive outlook for financial 2021 and reiterate, in line with the announcement on January 14, that while the costings of our vaccine distribution have yet to be determined, we expect to see a positive material difference to the company's year-end results," says Managing Director Nazmul Hassan.
Current stock price: 92.00 pence, up 1.7% on Thursday
Year-to-date change: down 5.7%
By Zoe Wickens; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Beximco Pharma